|
| Novel plant microRNAs from broccoletti sprouts do not show cross-kingdom regulation of pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.27527
Xi Xiao, Carsten Sticht, Libo Yin, Li Liu, Svetlana Karakhanova, Yefeng Yin, Christina Georgikou, Jury Gladkich, Wolfgang Gross, Norbert Gretz, Ingrid Herr
|
| 1203-1217 |
|
| A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy |
|
https://doi.org/10.18632/oncotarget.27529
Nagi B. Kumar, Julio Pow-Sang, Philippe Spiess, Shohreh Dickinson, Michael J. Schell
|
| 1218-1234 |
|
| A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies |
|
https://doi.org/10.18632/oncotarget.27530
Matthew H. Taylor, Ajjai S. Alva, Timothy Larson, Sebastian Szpakowski, Das Purkaystha, Alpesh Amin, Linda Karpiak, Sarina A. Piha-Paul
|
| 1235-1243 |
|
| Does breast carcinoma belong to the Lynch syndrome tumor spectrum? – Somatic mutational profiles vs. ovarian and colorectal carcinomas |
|
https://doi.org/10.18632/oncotarget.27538
Noora K. Porkka, Alisa Olkinuora, Teijo Kuopio, Maarit Ahtiainen, Samuli Eldfors, Henrikki Almusa, Jukka-Pekka Mecklin, Päivi Peltomäki
|
| 1244-1256 |
|
| Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells |
|
https://doi.org/10.18632/oncotarget.27545
David J. Lamb, Aleksander Rust, Albin Rudisch, Tobias Glüxam, Nathalie Harrer, Herwig Machat, Ingrid Christ, Florian Colbatzky, Andreas Wernitznig, Annika Osswald, Wolfgang Sommergruber
|
| 1257-1272 |
|
| First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients |
|
https://doi.org/10.18632/oncotarget.27549
Natalia V. Eremina, Vasily I. Kazey, Sergey V. Mishugin, Roman V. Leonenkov, Dmitry Y. Pushkar, Vadim L. Mett, Andrei V. Gudkov
|
| 1273-1288 |
|
| Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
|
https://doi.org/10.18632/oncotarget.27407
Sunkyu Kim, Ralph Tiedt, Alice Loo, Thomas Horn, Scott Delach, Steven Kovats, Kristy Haas, Barbara Schacher Engstler, Alexander Cao, Maria Pinzon-Ortiz, Iain Mulford, Michael G. Acker, Rajiv Chopra, Christopher Brain, Emmanuelle di Tomaso, William R. Sellers, Giordano Caponigro
|
| 1289-1289 |
|
| Correction: Exclusive destruction of mitotic spindles in human cancer cells |
|
https://doi.org/10.18632/oncotarget.27499
Leonid Visochek, Asher Castiel, Leonid Mittelman, Michael Elkin, Dikla Atias, Talia Golan, Shai Izraeli, Tamar Peretz, Malka Cohen-Armon
|
| 1290-1291 |
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
